AIM ImmunoTech
34 hedge funds and large institutions have $3.36M invested in AIM ImmunoTech in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 3 closing their positions.
6% less funds holding
Funds holding: 36 → 34 (-2)
28% less capital invested
Capital invested by funds: $4.68M → $3.36M (-$1.32M)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$20.6K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$6.93K |
| 3 |
Renaissance Technologies
New York
|
+$3.15K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$560 |
| 5 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$350 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$141K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$24K |
| 3 |
VF
Virtu Financial
New York
|
-$10.4K |
| 4 |
Jane Street
New York
|
-$8K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Osaic Holdings
Scottsdale,
Arizona
| $2K | – | – | – |
|
|
HI
27
Hoey Investments
Coatesville,
Pennsylvania
| $1K | – | – | – |
|
|
SC
28
Stephens Consulting
Flint,
Michigan
| $873 | – | – | – |
|
|
TWC
29
TD Waterhouse Canada
Toronto,
Ontario, Canada
| $134 | – | – | – |
|
|
APA
30
American Portfolios Advisors
Holbrook,
New York
| $133 | – | – | – |
|
|
TSS
31
Two Sigma Securities
New York
| – | -$24K | -312 | Closed |
|
|
32
Jane Street
New York
| – | -$8K | -104 | Closed |
|
|
33
Wells Fargo
San Francisco,
California
| – | -$7K | -100 | -93% |
|
|
CFGS
34
Concourse Financial Group Securities
Birmingham,
Alabama
| – | -$350 | -5 | Closed |
|
35
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$280 | +4 | New |
|
AIM Hedge Fund Activity: Q3 2022 in Review
34 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in AIM ImmunoTech (AIM) for Q3 2022, worth a combined $3.36M — down 28% from $4.68M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of AIM and 2 opened new positions — a net loss of 1 holder — while 7 trimmed existing stakes and 4 added.
The largest buyer was Millennium Management, opening a new position worth an estimated $20.6K. The largest seller was Morgan Stanley, cutting an estimated $141K.
- 34 institutional investors held AIM ImmunoTech (AIM) as of Q3 2022, down from 36 in Q2 2022.
- Funds reported $3.36M of AIM ImmunoTech stock for Q3 2022, down 28% quarter-over-quarter.
- 2 funds opened new AIM ImmunoTech positions in Q3 2022 and 3 closed out, a net change of -1 holder.
- The largest AIM ImmunoTech buyer in Q3 2022 was Millennium Management, an estimated $20.6K added.
- The largest AIM ImmunoTech seller in Q3 2022 was Morgan Stanley, an estimated $141K sold.
Based on aggregated 13F filings for Q3 2022.